Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3E9 anti-MBG monoclonal antibody is a murine IgG1 monoclonal antibody that specifically binds and neutralizes marinobufagenin (MBG), an endogenous bufadienolide cardiotonic steroid. MBG inhibits Na/K-ATPase activity and is implicated in pathological states such as uremic cardiomyopathy, preeclampsia, and NaCl-sensitive hypertension. 3E9 mAb selectively targets MBG and exhibits minimal cross-reactivity with other bufadienolides and no cross-reactivity with cardenolide sodium pump inhibitors or other steroid hormones. In preclinical models, administration of 3E9 mAb lowers blood pressure, reverses cardiac hypertrophy and fibrosis, and restores Na/K-ATPase activity. Its mechanism is immunoneutralization of MBG, thereby opposing the associated inhibition of Na/K-ATPase and subsequent downstream pathologic effects[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3E9 anti-MBG monoclonal antibody.